Clinical, genetic and quality-of-life study of a cohort of adult patients with tuberous sclerosis.

dc.contributor.authorDe Sautu De Borbón, Elena Cristina
dc.contributor.authorGuerra Vales, Juan Manuel
dc.contributor.authorLumbreras Bermejo, Carlos
dc.contributor.authorGuerrero Ramos, Felix
dc.contributor.authorBuj Padilla, María José
dc.contributor.authorGonzález de la Aleja, Jesús
dc.contributor.authorMorales Conejo, Montserrat
dc.date.accessioned2025-01-07T13:22:17Z
dc.date.available2025-01-07T13:22:17Z
dc.date.issued2021-05-31
dc.description.abstractTuberous sclerosis (TS) is a condition whose manifestations in childhood have been extensively described, but whose presentation in adults is less well known. This study describes the clinical and genetic characteristics, therapeutic management and quality of life of a cohort of adult patients with TS. A comparative study of the characteristics of patients diagnosed in childhood and adulthood is also carried out. This observational, retrospective, cross-sectional study included a large cohort of adult patients (≥ 16 years old) followed for 5 years in a specific rare diseases unit. Fifty-seven patients with a diagnosis of tuberous sclerosis were included, more than 50% of whom were diagnosed as adults. The mean age of the patients was 42 years (20-86). The central nervous system was the main area affected (97%), followed by the skin (80.7%) and kidneys (73%). The most frequent genetic alteration was a mutation in the TSC2 gene (47.7%). Among patients diagnosed in adulthood, there was less neurological involvement, with less frequency of epileptic seizures (30.8% vs 60.79% of patients diagnosed in childhood) and astrocytomas (3.8% vs 53.6%), less intellectual disability (11.5% vs 71.4%) and less expressiveness of the condition. 42% of patients were treated with mTOR pathway inhibitors, and presence of an angiomyolipoma was the main indication. In a quality-of-life analysis, the means of the summary indices were below the scores of the average Spanish population: (47.42 (SD ± 9.82) on the physical health scale, 45.61 (SD ± 7.99) on the mental health scale) versus 50 (SD ± 10) for the general population. Up to 50% of adult patients with TS were diagnosed in adulthood, and the condition is less severe with less frequent epileptic seizures and intellectual disability. 42% require treatment with mTOR inhibitors, in most cases due to the presence of AMLs. The quality of life of adult patients with TS is diminished compared to the general population.
dc.identifier.doi10.1186/s13023-021-01878-2
dc.identifier.essn1750-1172
dc.identifier.pmcPMC8165982
dc.identifier.pmid34059113
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8165982/pdf
dc.identifier.unpaywallURLhttps://ojrd.biomedcentral.com/counter/pdf/10.1186/s13023-021-01878-2
dc.identifier.urihttps://hdl.handle.net/10668/25458
dc.issue.number1
dc.journal.titleOrphanet journal of rare diseases
dc.journal.titleabbreviationOrphanet J Rare Dis
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.page.number243
dc.pubmedtypeJournal Article
dc.pubmedtypeObservational Study
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAdult
dc.subjectMultidisciplinary unit
dc.subjectQuality of life
dc.subjectTuberous sclerosis
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAngiomyolipoma
dc.subject.meshCross-Sectional Studies
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshQuality of Life
dc.subject.meshRetrospective Studies
dc.subject.meshTuberous Sclerosis
dc.subject.meshYoung Adult
dc.titleClinical, genetic and quality-of-life study of a cohort of adult patients with tuberous sclerosis.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number16

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8165982.pdf
Size:
768.38 KB
Format:
Adobe Portable Document Format